Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease. Congenit Heart Dis 2007;2(3):194-8
Date
04/02/2008Pubmed ID
18377465DOI
10.1111/j.1747-0803.2007.00097.xScopus ID
2-s2.0-34250171137 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Epoprostenol is a potent arterial vasodilator, and its administration by inhalation localizes its effects to the pulmonary circulation. In this case report, we describe a 3-month-old male patient with significant refractory pulmonary hypertension after pulmonary artery banding and placement of a Blalock-Taussig shunt. This patient continued to have significant hypoxic episodes despite maximal therapy with sedation, alkalinization, sildenafil, and inhaled nitric oxide. After the addition of inhaled epoprostenol, improvements in both clinical response and echocardiography-based hemodynamics were observed. The case supports a synergistic role among the agents in the treatment of pulmonary arterial hypertension from congenital heart disease.
Author List
Kovach J, Ibsen L, Womack M, Steusse D, Law YMAuthor
Joshua Kovach MD Associate Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Administration, InhalationBlood Vessel Prosthesis
Epoprostenol
Heart Defects, Congenital
Heart Septal Defects, Ventricular
Humans
Hypertension, Pulmonary
Infant
Ligation
Male
Pulmonary Artery
Transposition of Great Vessels
